Key facts
- This page summarizes Robert Francomano's Form 4 filing for SELLAS Life Sciences Group, Inc. (SLS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Jan 2024, 06:02.
Robert Francomano - 22 Jan 2024 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- SLS
- Reported as of
- 22 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jan 2024, 06:02:10 UTC
- Prior SEC filing
- 08 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Francomano
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Francomano filed Form 4 for SELLAS Life Sciences Group, Inc. (SLS) on 25 Jan 2024.
Change
- Previous filing in this sequence was filed on 08 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- +96%
- Price
- $0.000000
- Shares after
- 40,918
- Date
- 22 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 22 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $0.5195
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
Footnote F2
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.